Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multi-target CAR-T cells (Second Affiliated Hospital of Guangzhou Medical University)
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Parenteral
01
Overview
These third-generation chimeric antigen receptor (CAR) T-cell therapies are developed by the Second Affiliated Hospital of Guangzhou Medical University for the treatment of advanced lung cancer and other solid tumors. The program utilizes CAR-T cells engineered to target thirteen different tumor-associated antigens: GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, and EGFR. These candidates are being evaluated in Phase I clinical trials to assess their safety, tolerability, and preliminary efficacy, either as monotherapies or in combination, to address the challenge of tumor heterogeneity in solid malignancies. The third-generation CAR construct typically includes multiple costimulatory domains to enhance T-cell persistence and anti-tumor activity.
- Other names
- GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cellsCAR-T cells-Second Affiliated Hospital of Guangzhou Medical University-lung cancer-advanced solid tumors
02
Targets
GUCY2C (Guanylate cyclase C receptor)MesothelinLeY (Lewis Y antigen)PSCA (Prostate stem cell antigen)ERBB2 (Erb-b2 receptor tyrosine kinase 2)Claudin 18.2TGFB (GARP–latent transforming growth factor beta 1 complex)GPC3 (Glypican-3)B7-H3MUC (Mucin family)
Beyond the preview
Go deeper on Multi-target CAR-T cells (Second Affiliated Hospital of Guangzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multi-target CAR-T cells (Second Affiliated Hospital of Guangzhou Medical University).